
THOMAS OPLADEN

CV

PARTICIPANT AT:

CONNECTING THE GROWING BRAIN UNDERSTANDING NEUROPAEDIATRIC DISEASES THROUGH SYNAPTIC COMMUNICATION

**November, 26th-27th, 2015, Barcelona**

Thomas Opladen, Consultant for Child Neurology and Inborn Errors of Metabolism, Division of Child Neurology and Metabolic Medicine, University Children Hospital Heidelberg, Heidelberg, Germany

Thomas Opladen got his Degree in Paediatrics in 2008, he then got specialised in paediatric metabolic medicine in 2009. In 2011 he got specialisation in paediatric intensive care medicine, and in 2015 he got specialization in paediatric neurology. All of them by the University Children's Hospital Heidelberg, in Germany. He completed his Venia legend (Habilitation) in 2014. Since 2014 he is te coordinator of the iNTD network (International Working Group on Neurotransmitter related Disorders), and Consultant for Child Neurology and Inborn Errors of Metabolism.

B-DEBATE IS AN INITIATIVE OF:



THOMAS OPLADEN

ABSTRACT

PARTICIPANT AT:

CONNECTING THE GROWING BRAIN UNDERSTANDING NEUROPAEDIATRIC DISEASES THROUGH SYNAPTIC COMMUNICATION

**November, 26th-27th, 2015, Barcelona**

Thomas Opladen, Consultant for Child Neurology and Inborn Errors of Metabolism, Division of Child Neurology and Metabolic Medicine, University Children Hospital Heidelberg, Heidelberg, Germany

The iNTD Registry: A New Clinical Database of Patients with Inborn Neurotransmitter, Pterin and Folate Disorders

Inherited defects of neurotransmitter (biogenic amines), tetrahydrobiopterin (BH4) and folate metabolism lead to progressive neurological dysfunction in early infancy. Immediate diagnosis and treatment may result in an improved outcome. Until today there is no standardized systemic evaluation of diagnostic processes, therapeutic approaches and long term outcome of affected patients. The new "International Working Group on Neurotransmitter Related Disorders" (iNTD) provides a platform for the scientific and clinical exchange in the field of neurotransmitter related disorders. It includes 23 metabolic centers from 17 countries worldwide. The newly developed web-based iNTD patient registry for inherited defects of neurotransmitter, pterin and folate metabolism enables a standardized assessment of the epidemiology, genotype/phenotype correlation and outcome of these diseases, their impact on the quality of life of patients, and current diagnostic and therapeutic strategies. Based on the evaluation of the patient registry recommendations for the clinical and therapeutic management will be developed. The iNTD network is a growing international initiative to encourage scientific and clinical exchange on neurotransmitter related disorder. Together with the iNTD registry it aims to improve current research, basic knowledge and clinical management strategies considering the rare neurotransmitter related diseases.

B-DEBATE IS AN INITIATIVE OF:

